When the world gets closer.

We help you see farther.

Sign up to our expressly international daily newsletter.


Introducing The 'Polypill' - Should Everyone Over 50 Start Taking This Wonder Drug?

Set to be available in the US this year, this mixture of medicines in one pill is aimed at reducing heart attacks. Its inventor says even middle age people with no symptons should take it.

The race for longer lives
The race for longer lives
Francesca Sacco

GENEVA - It is being billed as a revolutionary pill, and will soon be available in pharmacies in the United States. Its backers recommend it to every single person over the age of 50.

Releasing a pill as a way to help prevent heart disease to anyone of middle age and older -- whether or note they have symptoms -- is the idea of Professor Nicholas Wald of the London-based Wolfson Institute of Preventive Medicine.

His “Polypill” might very well land on the US market early in 2013, according to an article last fall by Dr. Gérard Waeber, a prominent Swiss physician.

The Polypill, as its name implies, is a mix of different substances. Some of the medicines are new, others have long been available. Though the formula isn’t final yet, it is expected to contain beta-blockers to slow the heart rate, an antiplatelet agent to increase blood flow and an anti-cholesterol agent. Think of the Polypill as some sort of pharmaceutical “three-in-one” shampoo.

Aging, as Professor Wald notes, is the main factor responsible for heart disease. The goal of Wald and his team of researchers is to bring the first Polypill to market that is recommended to absolutely everyone over 55. The pill is touted as having been able to prevent heart attacks in 28% of the population for a decade.

Even if half of the people over 50 took the Polypill, 94,000 heart attacks and strokes would be avoided each year in Great Britain, Wald claimed in 2011 in a press release of London’s Queen Mary University. He also published a research paper In the magazine PlosOne testifying that the Polypill has "enormous potential in terms of prevention.” He suggested that this medicinal cocktail would diminish arterial pressure by 12% and the “bad” cholesterol by 39%, leading to a predictable reduction of the number of heart attacks by 60%.

To grasp the full potential of this Polypill, you need to know that heart disease is the No. 1 cause of death in countries with a high GDP. Arterial hypertension – one of the first controllable factors of risk -- touches 35% of the population over 50, and this number reaches 45% past 60.

According to cardiology professor Salim Uusuf from McMaster university in Hamilton Canada, the Polypill must be considered “not as a pill but a different approach to prevention.” It is also relatively inexensive: 57 euros per person a year. Composed of generic pill materials, it can be sold in pharmacies.

However, ever since the first tests began in 2000, people have criticized the approach of suggesting medical substances to healthy people. “The inventors of this pharmaceutical concept want a generalization of the Polypill prescriptions that would render the tracing process and medical monitoring obsolete,” says the Swiss physician Waeber.

The economic advantages would include fewer doctor appointments and lower costs for future medical expenses. “From a medical point of view, we have no idea if it’s a good measure or not," adds Waeber. "Before the symptoms kick in, there is a simple way to alter the risks, and that is a better everyday health. After that, customized treatment turns out to be the most satisfying solution.”

The Polypill clearly has not convinced the entire medical community. Some doctors reckon that it would be interesting to distribute several formulas, for different groups of patients, depending on the level of risk they face.

Waeber ultimately sees the risk of a supposed "wonder pill" that could make people less attentive than they would otherwise be about both nutrition and exercise.

You've reached your limit of free articles.

To read the full story, start your free trial today.

Get unlimited access. Cancel anytime.

Exclusive coverage from the world's top sources, in English for the first time.

Insights from the widest range of perspectives, languages and countries.


Lithium Mines In Europe? A New World Of Supply-Chain Sovereignty

The European Union has a new plan that challenges the long-established dogmas of globalization, with its just-in-time supply chains and outsourcing the "dirty" work to the developing world.

Photo of an open cast mine in Kalgoorlie, Australia.

Open cast mine in Kalgoorlie, Australia.

Pierre Haski


PARIS — It is one of the great paradoxes of our time: in order to overcome some of our dependencies and vulnerabilities — revealed in crises like COVID and the war in Ukraine — we risk falling into other dependencies that are no less toxic. The ecological transition, the digitalization of our economy, or increased defense needs, all pose risks to our supply of strategic minerals.

The European Commission published a plan this week to escape this fate by setting realistic objectives within a relatively short time frame, by the end of this decade.

This plan goes against the dogmas of globalization of the past 30 or 40 years, which relied on just-in-time supply chains from one end of the planet to the other — and, if we're being honest, outsourced the least "clean" tasks, such as mining or refining minerals, to countries in the developing world.

But the pendulum is now swinging in the other direction, if possible under better environmental and social conditions. Will Europe be able to achieve these objectives while remaining within the bounds of both the ecological and digital transitions? That is the challenge.

Keep reading...Show less

You've reached your limit of free articles.

To read the full story, start your free trial today.

Get unlimited access. Cancel anytime.

Exclusive coverage from the world's top sources, in English for the first time.

Insights from the widest range of perspectives, languages and countries.

The latest